unverified · Source version 21589 · locator unknown
Congressman Jared Moskowitz (D-FL-23) joined colleagues to introduce the Affordable Loans for Students Act, saying the legislation moves forward by capping student loan interest rates at 2% across the board. While this is about student loans rather than prescription drugs, it is the clearest recent official example of Moskowitz pursuing affordability legislation through Congress.
Unverified model/legacy excerpt; not proof. AI summary (separate from source): Shows an active legislative pattern on lowering consumer costs, but not prescription drugs specifically.
unverified · Source version 21585 · locator unknown
The office announced a federal grant for a local arts project and emphasized helping students and families. This is constituent-service activity, not prescription-drug policy action.
Unverified model/legacy excerpt; not proof. AI summary (separate from source): No direct evidence on prescription drug costs; included only as recent official activity showing ongoing office work.
unverified · Source version 21590 · locator unknown
The Clerk’s member page shows Jared Moskowitz serving as Florida’s 23rd District representative in the 119th Congress and lists his committee assignments, confirming active federal office during the current term.
Unverified model/legacy excerpt; not proof. AI summary (separate from source): Confirms Moskowitz remains in active federal office, but contains no prescription-drug-specific delivery evidence.
unverified · Source version 53773 · locator unknown
The official office homepage shows recent 2026 updates and ongoing constituent services and press activity, but no specific prescription-drug-cost accomplishment or bill tied to that issue in the lookback window.
Unverified model/legacy excerpt; not proof. AI summary (separate from source): No concrete prescription-drug policy delivery found in the recent official office updates.
unresolvedsame_term
Home
primary · model gpt-5.4-mini · confidence 90%
unverified · Source version 21592 · locator unknown
The Clerk’s committee page lists Jared Moskowitz as a Democrat on the Oversight and Intelligence Subcommittee in the 119th Congress, confirming continued participation in House committee work during the current term.
Unverified model/legacy excerpt; not proof. AI summary (separate from source): Confirms ongoing committee service, but no direct evidence of prescription-drug-cost action.
unverified · Source version 21593 · locator unknown
This recorded House vote shows Moskowitz participated in floor action in late April 2026, demonstrating active legislative engagement in the lookback window, but the vote shown is not related to prescription-drug costs.
Unverified model/legacy excerpt; not proof. AI summary (separate from source): Recent House voting activity confirms engagement, but not delivery on the drug-cost claim.
unverified · Source version 21594 · locator unknown
This recent House roll call provides another instance of active participation in chamber business during May 2026, but no prescription-drug-cost-specific measure is evident from the vote page itself.
Unverified model/legacy excerpt; not proof. AI summary (separate from source): Shows continued legislative participation; no direct evidence for the prescription-drug-cost promise.
unverified · Source version 53749 · locator unknown
Rep. Moskowitz, Jared [D-FL-23] 12/10/2025
Unverified model/legacy excerpt; not proof. AI summary (separate from source): Congress.gov records Moskowitz as a cosponsor of H.R. 3069, the Medicare for All Act, on December 10, 2025; this is concrete work on a health-cost bill relevant to prescription drug affordability, but not enactment.
unverified · Source version 53751 · locator unknown
Prescription drugs and medical devices, including outpatient prescription drugs, medical devices, and biological products
Unverified model/legacy excerpt; not proof. AI summary (separate from source): The bill Moskowitz cosponsored expressly includes outpatient prescription drugs among covered benefits, connecting his cosponsorship to prescription-drug affordability policy.
unverified · Source version 53751 · locator unknown
The prices to be paid for covered pharmaceuticals, medical supplies, medical technologies, and medically necessary equipment covered under this Act shall be negotiated annually by the Secretary.
Unverified model/legacy excerpt; not proof. AI summary (separate from source): H.R. 3069 contains a prescription-drug price negotiation mechanism, so Moskowitz's cosponsorship is a concrete attempt to reduce drug costs, though still not enacted.
unverified · Source version 53749 · locator unknown
This bill has the status Introduced
Unverified model/legacy excerpt; not proof. AI summary (separate from source): Congress.gov still lists the relevant bill as introduced, so Moskowitz's prescription-drug-cost effort has not become enacted federal policy.
Vote #01: Final Passage – H.R. 6610, the Pharmacists Fight Back [in FEHB Plans Act]. The bill passed by a recorded vote of 40-2.
Fetched verbatim passage. AI summary (separate from source): In the lookback-adjacent official record, a separate prescription-drug/PBM bill advanced in committee, but the record does not show Moskowitz as a sponsor, cosponsor, or voter on that committee action; it does not deliver his commitment.
unverified · Source version 66522 · locator unknown
Sep 16, 2026, 07:05 PM | 119th Congress, 2nd Session
Roll Call Number: 314 | Bill Number: S. 2403
Vote Question: On Motion to Suspend the Rules and Pass
Bill Title & Description: Retire through Ownership Act
Unverified model/legacy excerpt; not proof. AI summary (separate from source): The Clerk's latest House vote feed in the lookback window shows recent floor activity, but the visible recent measures are not prescription-drug-cost legislation tied to Moskowitz.
unverified · Source version 66524 · locator unknown
Roll Call 302 | Bill Number: H. R. 8278
Sep 15, 2026, 10:03 PM | 119th Congress, 2nd Session
Vote Question: On Motion to Suspend the Rules and Pass, as Amended
Fostering the Use of Technology to Uphold Regulatory Effectiveness in Supervision Act
Unverified model/legacy excerpt; not proof. AI summary (separate from source): Moskowitz participated in recent floor business during the lookback window, but this vote was not about prescription drug costs and does not deliver the commitment.
unverified · Source version 66526 · locator unknown
Vote on: Final Passage – H.R. 6610, the Pharmacists Fight Back [in FEHB Plans Act]
Date: 7/23/26 VOTE #: 1
Unverified model/legacy excerpt; not proof. AI summary (separate from source): A prescription-drug/PBM-related bill advanced in committee before the lookback window, but this roll-call sheet does not show Moskowitz participating in that committee vote, so it is not evidence of his own delivery or effort.
unverified · Source version 66528 · locator unknown
This bill has the status Introduced
Unverified model/legacy excerpt; not proof. AI summary (separate from source): Moskowitz's previously documented Medicare for All Act cosponsorship remains tied to an introduced bill rather than enacted federal policy, so the prescription-drug-cost promise remains unresolved.
Public state: unverifiedAs of unknown · legacy_unverified · . Original AI recommendation (not independently established): unresolved.unknown
The promise is broad—'will work to reduce prescription drug costs'—and the provided evidence does not show any prescription-drug-specific bill sponsorship, vote, amendment, executive action, public advocacy, or enacted result attributable to Jared Moskowitz. The evidence mostly confirms that he remains active in office and participating in House business, plus one affordability-related student-loan bill that is not about prescription drugs. Because there is no concrete evidence here either of delivery or of a serious attempt on this specific issue, the best judgment from this record is unresolved rather than delivered, partial, or never.